All In Biotech

NDA 207917 · Galderma Labs

Epiduo Forte

Adapalene, Benzoyl Peroxide · Topical · Retinoid

Last checked: Nov 20, 2026Latest source record: Apr 27, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2015

Jul 15, 2015

Approved uses

1

Original approval plus efficacy supplements

Registered trials

112

28 Phase 3, 7 recruiting

FAERS reports

54

22 serious, 0 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Aug 31, 2022.

Adapalene and Benzoyl Peroxide gel is indicated for the topical treatment of acne vulgaris in adults and pediatric patients 12 years of age and older. Adapalene and Benzoyl Peroxide gel, is a combination of adapalene, a retinoid, and benzoyl peroxide and is indicated for the topical treatment of acne vulgaris in adults and pediatric patients 12 years of age and older. ( 1 )

Mechanism: Adapalene Adapalene binds to specific retinoic acid nuclear receptors but does not bind to cytosolic receptor protein. Biochemical and pharmacological profile studies have demonstrated that adapalene is a modulator of cellular differentiation, keratinization and inflammatory processes. However, the significance of these findings with regard to the mechanism of action of adapalene for the treatment of acne is unknown. Benzoyl peroxide Benzoyl peroxide is an oxidizing agent with bactericidal and keratolytic effects.

Therapeutic areas: Ophthalmology

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • EPIDUO FORTE · ADAPALENE 0.3%; BENZOYL PEROXIDE 2.5% · GEL, TOPICAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Adapalene" as an intervention, any sponsor and status, largest first.

All 112 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective9
  • rash6
  • acne4
  • erythema4
  • application site pain3
  • application site pruritus3
  • burning sensation3
  • pruritus3
  • application site erythema2
  • application site irritation2
  • dermatitis atopic2
  • drug hypersensitivity2

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20132
20142
20151
20161
20171
20181
20197
20207
20213
20223
20236
202410
20257
20263

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Epiduo Forte (Adapalene/Benzoyl Peroxide)

2024 spending

$61K

Beneficiaries

36

87 claims

Per beneficiary

$1,690

$14.97 per unit

View as table
YearSpending
2020$469,833
2021$472,541
2022$149,509
2023$76,895
2024$60,855

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 219 on PubMed

Sponsor: Galderma Labs

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.